Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial

BACKGROUND: Management of type 2 diabetes with metformin often does not provide adequate glycemic control, thereby necessitating add-on treatment. In a 24-week clinical trial, dapagliflozin, an investigational sodium glucose cotransporter 2 inhibitor, improved glycemic control in patients inadequate...

Descripción completa

Detalles Bibliográficos
Autores principales: Bailey, Clifford J, Gross, Jorge L, Hennicken, Delphine, Iqbal, Nayyar, Mansfield, Traci A, List, James F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3606470/
https://www.ncbi.nlm.nih.gov/pubmed/23425012
http://dx.doi.org/10.1186/1741-7015-11-43

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3606470/
https://www.ncbi.nlm.nih.gov/pubmed/23425012
http://dx.doi.org/10.1186/1741-7015-11-43

Ejemplares similares